News

The company said that the data reported indicate that MDRNA’s dicer substrate small interfering RNAs (siRNAs) are highly active against multiple strains of influenza A virus including seasonal

However, the special committee would consider a proposal that recognizes the value of the company and reflects the significant benefits that would accrue to Roche as a result

It is reported that PMX-60056 represents an entirely new class of drug, which PolyMedix calls a heptagonist, and is reportedly the only reversing agent for heparin and the

MEDI-545 is a fully human antibody generated by Medarex’s UltiMAb Human Antibody Development System. Under the terms of the agreement, Medarex will receive a milestone payment of an

In April 2008, ImClone announced the establishment of an agreement with the FDA under a special protocol assessment for this trial. The SPA is a written agreement between

John Wayne Cancer Institute (JWCI) is the eighth center in this multi-center trial testing the company’s percutaneous hepatic perfusion system for the isolated, high-dose delivery of the anticancer

PRX-08066 is a serotonin type 2B receptor (5-HT2B) antagonist that may represent a new mechanism of action for treating pulmonary hypertension (PH). This single-arm, open-label, Phase IIb study

Concentric Medical and InTouch Health said that they will work with hospitals to create centers of excellence for treating acute ischemic stroke, developing comprehensive programs that offer patients

John Kovach, president and CEO of Lixte, said: “Lixte has developed a series of novel compounds that inhibit the growth of common brain cancers of adults and children